CN1557446A - Compound medicine for treating gout - Google Patents
Compound medicine for treating gout Download PDFInfo
- Publication number
- CN1557446A CN1557446A CNA2004100234392A CN200410023439A CN1557446A CN 1557446 A CN1557446 A CN 1557446A CN A2004100234392 A CNA2004100234392 A CN A2004100234392A CN 200410023439 A CN200410023439 A CN 200410023439A CN 1557446 A CN1557446 A CN 1557446A
- Authority
- CN
- China
- Prior art keywords
- medicine
- gout
- treatment
- radix
- compound medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 40
- 201000005569 Gout Diseases 0.000 title claims abstract description 20
- 150000001875 compounds Chemical class 0.000 title claims abstract description 19
- 239000008589 Cortex Fraxini Substances 0.000 claims description 13
- 241000237903 Hirudo Species 0.000 claims description 13
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 11
- 239000002994 raw material Substances 0.000 claims description 7
- 239000002552 dosage form Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 12
- 238000002360 preparation method Methods 0.000 abstract description 4
- 241000545744 Hirudinea Species 0.000 abstract 1
- 244000236658 Paeonia lactiflora Species 0.000 abstract 1
- 235000008598 Paeonia lactiflora Nutrition 0.000 abstract 1
- 241000219061 Rheum Species 0.000 abstract 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 abstract 1
- 241001404789 Smilax glabra Species 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 24
- 239000000284 extract Substances 0.000 description 16
- 238000002156 mixing Methods 0.000 description 11
- 208000002193 Pain Diseases 0.000 description 9
- 230000036407 pain Effects 0.000 description 9
- 239000000706 filtrate Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 5
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 4
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 4
- 210000003423 ankle Anatomy 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000010298 pulverizing process Methods 0.000 description 4
- 229940116269 uric acid Drugs 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010010774 Constipation Diseases 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 201000001431 Hyperuricemia Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000005096 rolling process Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 210000001226 toe joint Anatomy 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 235000019890 Amylum Nutrition 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 240000001307 Myosotis scorpioides Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 240000007509 Phytolacca dioica Species 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 210000000878 metatarsophalangeal joint Anatomy 0.000 description 1
- YJQPYGGHQPGBLI-KGSXXDOSSA-N novobiocin Chemical compound O1C(C)(C)[C@H](OC)[C@@H](OC(N)=O)[C@@H](O)[C@@H]1OC1=CC=C(C(O)=C(NC(=O)C=2C=C(CC=C(C)C)C(O)=CC=2)C(=O)O2)C2=C1C YJQPYGGHQPGBLI-KGSXXDOSSA-N 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 108010048734 sclerotin Proteins 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Abstract
The present invention relates to compound medicine for treating gout, and is especially one kind of compound gout treating Chinese medicine preparation. The compound medicine is prepared with medicine material including prepared rhubarb, smilax glabra rhizome, orienvine stem, ash bark, white peony root and leech. The medicine of the present invention has high curative effect, less side effect, high purity and taking convenience.
Description
(1) technical field under
The invention belongs to a kind of compound medicine for the treatment of gout, the compound preparation of the treatment gout that particularly a kind of pure Chinese medicine is made.
(2) background technology
Along with the raising of people's living standard, dietary structure changes and aged tendency of population, and the sickness rate of goat is increasing gradually.Wherein the treatment of hyperuricemia, gout lacks effective measures, can not effect a radical cure the Chang Fanfu outbreak.
(3) summary of the invention
The object of the present invention is to provide a kind of compound preparation of the treatment gout of being made by pure Chinese medicine, have evident in efficacyly, side effect is little.
The objective of the invention is to realize by following measure:
The present invention treats the compound medicine of gout, is to make by following weight proportion raw material and pharmaceutic adjuvant,
(ripe) Radix Et Rhizoma Rhei 3-10g Rhizoma Smilacis Glabrae 10-20g Caulis Sinomenii 10-20g
Cortex Fraxini 5-15g Chinese herbaceous peony 10-15g Hirudo 1-3g
Above-mentioned compound medicine, the optimal components ratio of its raw material is:
(ripe) Radix Et Rhizoma Rhei 4-8g Poria 10-20g Caulis Sinomenii 10-20g
Cortex Fraxini 6-12g Radix Paeoniae Alba 10-15g Hirudo 1-3g
Above-mentioned compound medicine, the best proportioning of its raw material is:
(ripe) Radix Et Rhizoma Rhei 6g Rhizoma Smilacis Glabrae 15g Caulis Sinomenii 15g
Cortex Fraxini 9g Radix Paeoniae Alba 12g Hirudo 1.5g
Above-mentioned compound medicine can be made capsule, tablet or other pharmaceutically acceptable dosage form.
1. the preparation method of medicine of the present invention
Get after (ripe) Radix Et Rhizoma Rhei, Hirudo and the Radix Paeoniae Alba mix, add 7-12 doubly the hexanol of (under the weight with) 50% extract 3 times, filter, merging filtrate, concentrating under reduced pressure, concentrated solution is standby.
Fetch earth after Poria, Caulis Sinomenii and the Cortex Fraxini mixing, the hexanol of 7-12 times of 80-90% of adding extracts 2 times, and the hexanol that adds 7-12 times of 50-60% extracts 1 time, filtration, and merging filtrate gets extracting solution.
After above-mentioned concentrated solution and extracting solution mixing, the concentrating under reduced pressure drying gets extractum, gets extract powder after the pulverizing.Add pharmaceutically useful adjuvant, make suitable dosage form.
2. the clinical experiment of medicine of the present invention
2.1 tcm diagnosis standard
The tcm diagnosis standard is (with reference to People's Republic of China's Chinese medicine industry standard (ZY/001-94) tcm internal medicine disease diagnosis criterion of therapeutical effect.)
1. how with the right red and swollen heat pain of single finger toe joint soldier, pain is acute gradually, and very show effect repeatedly light night in daytime.Can be with heating, headache, disease such as weak.
2. be more common in aging male, the gout family history can be arranged.Often because of fatigue, eating and drinking too much at one meal is eaten high purine food, drinks and feels wind and cold etc. and bring out.
3. from the beginning of simple joint morbidity, with first metatarsophalangeal joints for seeing more.Continue then ankle, with, point other little joints and red and swollen heat pain occurs, very then articular cavity can have sepage.After the outbreak, can " piece scrofula " (tophus) appear with reaching around the joint between auricle and toe, phalanges repeatedly.
4. blood uric acid, the acid of urinating are increased.Stage of attack,, total white blood cells can increase.
5. make the kidney B-mode ultrasound tomography in case of necessity and survey, inspections such as routine urinalysis, renal function are to understand gout metanephros pathological changes situation.The X line is taken the photograph the sheet inspection: the sclerotin that can show cartilage edge adjacent joints has irregular round defect of giving a farfetched interpretation.
2.2 get rid of the case standard
1. be secondary to the secondary gout of other diseases.
2. irritated and can not anti-receptor to this medicine.
3. serious hepatic and kidney function obstacle; Hypertension influences the heart, brain, kidney person, and jaundice person is arranged; The psychotic.
4. big loose stool is thin or long-term diarrhea history person arranged.
5. do not meet not medication in accordance with regulations of the standard of including in, can't judge curative effect or data not umbra sound curative effect and safety judgement person.
2.3 analysis of clinical
The 33 routine patients of this observation are Hospital Attached to Shandong Chinese Medical Univ.'s outpatient service and inpatient.Inpatient's 8 examples wherein, outpatient's 25 examples, 33 examples are all the male.The oldest person 81 years old, reckling 28 years old.Average X=42.62 ± 15.18 years old.The course of disease is the longest 11 years, and is the shortest 2 months, average 4.57 ± 3.64 years.
Table 1 patient ordinary circumstance is analyzed
The sex course of disease (year)
The case load age
Men and women≤1≤5 10＞10
33 42.62±15.18 33 0 2 28 2 1
Table 2 first attack inducement is analyzed
The heavy meal tired wound of drinking is suffered from cold other
Total routine number
n ％ n ％ n ％ n ％ n ％
33 14 42.36 6 18.18 2 6.06 5 15.15 8 23.64
The analysis of table 3 complication
Nephropathy becomes
Total routine number blood pressure diabetes hyperlipidemia prostatosis
n ％
33 2 21 16 2 19 5
Table 4 painful area analysis (during first visit)
Two ankle first sole of the foot ankles of single ankle, sole of the foot toe upper and lower extremities
Sum
Toe joint joint, joint, joint all has
33 9 3 9 11 1
The analysis of table 5 picture of the tongue
The tongue body tongue body and tongue coating
Sum
The greasy white greasy thin white BOHUANG of the fat big normal dim Huang of modest light red purple
33 18 12 3 17 7 9 16 14 1 2
Table 6 pulse analysis
The heavy fine number of the sliding real stringy and rolling pulse of sum is counted accurately thin and delicate
33 13 7 6 2 3 2
Other performances of table 7 are analyzed
Joint osteoderm matter
Sum tophus constipation hyperuricemia
The dim red destruction of skin
33 2 31 29 4 33
2.4 the function of the medicine of invention cures mainly and instructions of taking
Treatment gout compound medicine of the present invention has heat-clearing and toxic substances removing, treatment of arthritis and promoting collateral and channels, relieving spasm to stop pain.Be used for causing that by accumulateing in the damp and hot turbid poison joint congestion and swelling pain is violent companion's obesity, vexed uneasiness, constipation, dark coloured urine, red tongue, the gout acute attack stage of rolling pulse or its catabasis.Each 3 of treatment gout compound medicine of the present invention, oral every day 2-3 time, one month is a course of treatment.
2.5 efficacy analysis
Curative effect judging standard, (with reference to People's Republic of China's Chinese medicine industry standard (ZY/001-94) tcm internal medicine disease diagnosis criterion of therapeutical effect)
Cure: transference cure, lab testing is normal
Take a turn for the better: arthroncus is subdued, pain relief, and lab testing has improvement.
Do not heal: symptom and lab testing no change.
33 routine patients cure 6 examples, effective 24 examples, 3 examples that do not heal, total effective rate 90.9%.Prophylactic is recidivist's 4 examples not; Outbreak is slight, and pain can be born receptor's 12 examples; Outbreak reduces, pain relieving person's 11 examples of need taking medicine in addition during outbreak; Nonresponder's 6 examples.
Table 8 efficacy analysis
Cure and effectively do not heal
Sum
n ％ n ％ n ％
Treat 33 6 18.18 24 72.73 3 9.09
Prevent 33 4 12.12 23 69.70 6 18.18
Blood uric acid analysis (X ± X before and after table 9 treatment
n)
Treatment back P value before the treatment
Blood uric acid (umol/L) 428.39 ± 49.30 394.77 ± 71.64＜0.05
CRP(mg/L) 6.14±4.65 3.26±1.97 ＜0.05
Blood glucose (mmol/L) 4.61 ± 0.73 4.55 ± 1.62＞0.05
Triglyceride (mmol/L) 3.10 ± 0.92 1.72 ± 0.87 0.05
Table 10 clinical manifestation analysis
Treatment back effective percentage (%) before the treatment
Arthralgia several 41 16 60.98
Arthroncus several 41 13 68.29
Greasy fur on tongue 30 11 63.33
Rolling pulse 23 18 17.40
Constipation 29 2 93.10
In sum, medicine of the present invention has that therapeutic effect is good, evident in efficacy, and side effect is little, is made purity height, taking convenience by pure Chinese medicine.
The pharmaceutical research of 3 medicines of the present invention
Cause scorching experimentation 1. for the scorching experiment of mouse ear caused by dimethylbenzene xylene, the short sole of the foot formaldehyde of mice, the result shows: medicine of the present invention has the effect that obviously reduces inflammation.
2. cause experiment and mice Re Baifa causes the pain experimentation through mice acetic acid, the result shows: medicine of the present invention has significant analgesia role.
3. through immune function experiment research, the result shows: medicine of the present invention has the effect that improves non-specific macrophage immunity function and specific cellular immunity function.
4. through the experimentation to the hyperuricemia rat, the result shows: medicine of the present invention has the reduction blood uric acid, the effect of triglyceride, blood viscosity and blood glucose.
(4) specific embodiment
Embodiment 1:
The composition of raw materials of present embodiment is: (ripe) Radix Et Rhizoma Rhei 9kg, Rhizoma Smilacis Glabrae 10kg, Caulis Sinomenii 20kg, Cortex Fraxini 7kg, Radix Paeoniae Alba 11kg, Hirudo 3kg.
After getting (ripe) Radix Et Rhizoma Rhei, Hirudo and Radix Paeoniae Alba mixing, the hexanol that adds 10 times 50% extracts 3 times, filter, and merging filtrate, concentrating under reduced pressure, it is standby to get concentrated solution.
Fetch earth after Poria, Caulis Sinomenii and the Cortex Fraxini mixing, the hexanol of 12 times of 80-90% of adding extracts 2 times, and the hexanol that adds 10 times of 50-60% extracts 1 time, filtration, and merging filtrate gets extracting solution.
After above-mentioned concentrated solution and extracting solution mixing, the concentrating under reduced pressure drying gets extractum, gets extract powder 8.2kg after the pulverizing.Add the magnesium stearate of 100g, encapsulated, the 0.4g/ grain.
Usage and consumption: oral, 2-3 time on the one, each 3, one month is a course of treatment.
Embodiment 2:
The composition of raw materials of present embodiment is: (ripe) Radix Et Rhizoma Rhei 4kg, Rhizoma Smilacis Glabrae 18kg, Caulis Sinomenii 12kg, Cortex Fraxini 13kg, Radix Paeoniae Alba 15kg, Hirudo 1kg.
After getting (ripe) Radix Et Rhizoma Rhei, Hirudo and Radix Paeoniae Alba mixing, the hexanol that adds 8 times 50% extracts 3 times, filter, and merging filtrate, concentrating under reduced pressure, it is standby to get concentrated solution.
Fetch earth after Poria, Caulis Sinomenii and the Cortex Fraxini mixing, the hexanol of 10 times of 80-90% of adding extracts 2 times, and the hexanol that adds 8 times of 50-60% extracts 1 time, filtration, and merging filtrate gets extracting solution.
After above-mentioned concentrated solution and extracting solution mixing, the concentrating under reduced pressure drying gets extractum, gets extract powder 7.8kg after the pulverizing.Add the 1000g amylum pregelatinisatum, be pressed into tablet, the 0.3g/ sheet.
Usage and consumption: oral, 3 times on the one, each 3, one month is a course of treatment.
Embodiment 3:
The composition of raw materials of present embodiment is: (ripe) Radix Et Rhizoma Rhei 6kg, Rhizoma Smilacis Glabrae 15kg, Caulis Sinomenii 15kg, Cortex Fraxini 9kg, Radix Paeoniae Alba 12kg, Hirudo 1.5kg.
After getting (ripe) Radix Et Rhizoma Rhei, Hirudo and Radix Paeoniae Alba mixing, the hexanol that adds 10 times 50% extracts 3 times, filter, and merging filtrate, concentrating under reduced pressure, it is standby to get concentrated solution.
Fetch earth after Poria, Caulis Sinomenii and the Cortex Fraxini mixing, the hexanol of 10 times of 80-90% of adding extracts 2 times, and the hexanol that adds 10 times of 50-60% extracts 1 time, filtration, and merging filtrate gets extracting solution.
After above-mentioned concentrated solution and extracting solution mixing, the concentrating under reduced pressure drying gets extractum, gets extract powder 8kg after the pulverizing.Add the magnesium stearate of 100g, encapsulated, the 0.4g/ grain.
Usage and consumption: oral, 2-3 time on the one, each 3, one month is a course of treatment.
Claims (5)
1. compound medicine for the treatment of gout is characterized in that: be to make by following weight proportion raw material and pharmaceutic adjuvant,
(ripe) Radix Et Rhizoma Rhei 3-10g Rhizoma Smilacis Glabrae 10-20g Caulis Sinomenii 10-20g
Cortex Fraxini 5-15g Radix Paeoniae Alba 10-15g Hirudo 1-3g
2. the compound medicine of treatment gout according to claim 1 is characterized in that:
(ripe) Radix Et Rhizoma Rhei 4-8g Rhizoma Smilacis Glabrae 10-20g Caulis Sinomenii 10-20g
Cortex Fraxini 6-12g Radix Paeoniae Alba 10-15g Hirudo 1-3g
3. the compound medicine of treatment gout according to claim 1 is characterized in that:
(ripe) Radix Et Rhizoma Rhei 6g Rhizoma Smilacis Glabrae 15g Caulis Sinomenii 15g
Cortex Fraxini 9g Radix Paeoniae Alba 12g Hirudo 1.5g
4. according to the compound medicine of claim 1,2 or 3 described treatment gouts, it is characterized in that: described medicine is made capsule.
5. according to the compound medicine of claim 1,2 or 3 described treatment gouts, it is characterized in that: described medicine is made tablet or other pharmaceutically acceptable dosage form.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410023439 CN1241630C (en) | 2004-01-15 | 2004-01-15 | Compound medicine for treating gout |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410023439 CN1241630C (en) | 2004-01-15 | 2004-01-15 | Compound medicine for treating gout |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1557446A true CN1557446A (en) | 2004-12-29 |
| CN1241630C CN1241630C (en) | 2006-02-15 |
Family
ID=34352135
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410023439 Expired - Lifetime CN1241630C (en) | 2004-01-15 | 2004-01-15 | Compound medicine for treating gout |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1241630C (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1326553C (en) * | 2005-11-23 | 2007-07-18 | 安徽省药物研究所 | Medicine for treating gout and preparing method |
| CN102988640A (en) * | 2012-11-02 | 2013-03-27 | 樊梅 | External-use power for treating gout |
| CN104510759A (en) * | 2014-03-24 | 2015-04-15 | 广西卫生职业技术学院 | Medicinal use of gilt-edged leech |
| CN110433244A (en) * | 2019-09-12 | 2019-11-12 | 张伟夫 | A kind of preparation method of composition, gout tea bag and gout tea bag |
-
2004
- 2004-01-15 CN CN 200410023439 patent/CN1241630C/en not_active Expired - Lifetime
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1326553C (en) * | 2005-11-23 | 2007-07-18 | 安徽省药物研究所 | Medicine for treating gout and preparing method |
| CN102988640A (en) * | 2012-11-02 | 2013-03-27 | 樊梅 | External-use power for treating gout |
| CN102988640B (en) * | 2012-11-02 | 2014-06-04 | 樊梅 | External-use power for treating gout |
| CN104510759A (en) * | 2014-03-24 | 2015-04-15 | 广西卫生职业技术学院 | Medicinal use of gilt-edged leech |
| CN110433244A (en) * | 2019-09-12 | 2019-11-12 | 张伟夫 | A kind of preparation method of composition, gout tea bag and gout tea bag |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1241630C (en) | 2006-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1768812A (en) | Medicinal composition for removing dampness to relieve itching and its preparation method and uses | |
| CN1895642A (en) | Chinese-medicinal composition for treating neck, shoulder, waist and legs diseases and its making method | |
| CN1861163A (en) | Traditional Chinese medicine composition for treating kidney-yang deficiency and deficiency of vital energy and blood, its prepn. process | |
| CN100342889C (en) | Chinese medicine for treating gout | |
| CN1167454C (en) | Chinese medicine for detoxication purpose and its preparing process | |
| CN1726929A (en) | Compsn. of medication for treating diabetes | |
| CN1270746C (en) | Medicine for diminishing the inflammation and reducing the pain, subsiding swelling to dissipate indurated mass, dredging meridian to removing stagnation | |
| CN1256969C (en) | Chinese medicine for treating bone disease and its preparation | |
| CN1241630C (en) | Compound medicine for treating gout | |
| CN1840160A (en) | Powder for resisting hyperosteogeny | |
| CN1973878A (en) | Medicine for treating children's stomachache and its prepn | |
| CN1197614C (en) | Chinese medicine cap sule for treating prostatic disorders | |
| CN101032540A (en) | Medicine composition for curing arthritis and the preparing method and purpose thereof | |
| CN1254267C (en) | Medicine for treating gastral cavity pain and its preparation method | |
| CN1215595A (en) | External use medicine for treating soft tissue injury and its producing method | |
| CN1840101A (en) | Chinese medicine with wind-dispelling damp-eliminating, collaterals-dredging, coldness-expelling pain-relieving functions and preparation process thereof | |
| CN1203876C (en) | Medicine for curing postpartum subinvolution of uterus and its preparation method | |
| CN1471954A (en) | Chinese medicine for withdrawal of drug dependence | |
| CN1030373C (en) | Medicine for waist rheumatism | |
| CN1261156C (en) | Medicine for treating chronic gastroenteritis and colitis | |
| CN1850265A (en) | Chinese medicine for treating nephrosis Yang deficiency syndrome | |
| CN1411861A (en) | Medicine for curing acute injury of muscle and tendon and its preparation method | |
| CN1650959A (en) | Wine for dispelling wind and removing obstruction in channels and its preparation method | |
| CN1216634C (en) | Medicinal composition for treating pain | |
| CN1212132C (en) | Chinese medicine for treating rheumatic diseases and its prepn |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: GUANGZHOU JINGXIUTANG( PHARMACEUTICAL ) CO., LTD. Free format text: FORMER OWNER: GUANGZHOU JINGXIUTANG( PHARMACEUTICAL ) CO., LTD.; SHANDONG CHINESE MEDICINE UNIV. Effective date: 20070427 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20070427 Address after: 510130 No. 179 Renmin South Road, Guangdong, Guangzhou Patentee after: Guangzhou JingXiuTang Pharmaceutical Co.,Ltd. Address before: 510130 No. 179 Renmin South Road, Guangdong, Guangzhou Co-patentee before: Shandong University of Traditional Chinese Medicine Patentee before: Guangzhou JingXiuTang Pharmaceutical Co.,Ltd. |
|
| C56 | Change in the name or address of the patentee |
Owner name: GUANGZHOU BAIYUNSHAN JINGXIUTANG PHARMACEUTICAL CO Free format text: FORMER NAME: JINGXIUTANG (PHARMACEUTICAL) CO., LTD., GUANGZHOU;JINGXIUTANG (PHARMACEUTICAL) CO., LTD., GUANGZHOU |
|
| CP03 | Change of name, title or address |
Address after: 510130 No. 179 Renmin South Road, Guangzhou, Guangdong, Liwan District Patentee after: GUANGZHOU BAIYUNSHAN JINGXIUTANG PHARMACEUTICAL Co.,Ltd. Address before: 510130 No. 179 Renmin South Road, Guangdong, Guangzhou Patentee before: Guangzhou JingXiuTang Pharmaceutical Co.,Ltd. |
|
| CX01 | Expiry of patent term |
Granted publication date: 20060215 |
|
| CX01 | Expiry of patent term |